Andrea Small-Howard, Phd, Mba Email & Phone Number

Los Angeles, Ca, Us

Las Vegas, Nevada, Us

GB Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues that are identical to the original plant compounds but are produced under current Good Manufacturing Practices. GB Sciences' intellectual property portfolio contains 8 issued U.S. and 14 issued foreign patents, as well as 15 U.S. and 41 foreign patent-pending applications. In its drug development pipeline, GB Sciences has five preclinical phase product development programs. GB Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. GB Sciences' formulations for chronic pain are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). Recently, the company has received positive preclinical animal results supporting their novel formulations for stress and anxiety based on animal studies at the NRC. The company has also received positive preclinical proof-of-concept data supporting its complex cannabinoid mixtures for the treatment of Cytokine Release Syndrome based on preclinical studies at Michigan State University. GB Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Las Vegas, Nevada, Us

GB Sciences, Inc. (OTCQB: GBLX), through their Canadian entity, GbS Global Biopharma, Inc., is a plant-inspired biotech company developing patented formulations of plant-inspired, minimum essential mixtures for the prescription drug market.

Las Vegas, Nevada, Us

GB Sciences, Inc. (OTCQB: GBLX), through their Canadian entity, GbS Global Biopharma, Inc., is a plant-inspired biotech developing plant-inspired minimal essential mixtures (MEM) for the prescription drug market.

Las Vegas, Nevada, Us

GB Sciences, Inc. (OTCQB: GBLX) is a plant-inspired biopharma drug development company whose goal is to create patented formulations of plant-inspired, Minimal Essential Mixtures (MEM) for the prescription drug market that target a variety of medical conditions. The active ingredients in our MEM are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices (cGMP). Gb Sciences' novel drug discovery platform has yielded 6 issued US and 3 issued international patents, as well as 18 US and 40 international patent-pending applications. In our drug development pipeline, we have five preclinical stage programs, and our lead Parkinson's disease therapeutic program is being prepared for a First-in-Human clinical trial. In addition to Parkinson's disease, Gb Sciences is developing therapeutics for chronic pain, cytokine release syndrome (CRS), Mast Cell Activation Syndrome (MCAS), anxiety, depression, and heart failure. GB Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. https://gbsciences.com

GbS Global Biopharma (GbS) Inc. is a plant-based research and biopharmaceutical development company located in Ottawa, Canada. GbS Global Biopharma's proprietary drug discovery platform generates Active Pharmaceutical Ingredient (API) mixtures for a variety of medical indications. The company currently has Rx programs in late pre-clinical and their lead program in Parkinson's disease is being advanced towards the clinic. GbS is working with time released nanoparticles and rapid dissolve technology for effective oral delivery of their formulations in the prescription drug market.

Chicago, Illinois, Us

The Center for Healthcare Innovation is a non-profit, non-partisan, and independent organization committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation, particularly in the biotechnology, medical device, nanotechnology, and pharmaceutical sectors. The CHI vision is to become the world’s #1 independent thought-leadership institution and “think tank” for the global pharmaceutical and life sciences community.

International Biotechnology Solutions creates customized, cost-effective commercialization solutions for viable yet abandoned biopharma products. Based on our understanding that the paradigm by which biotechnology and pharmaceutical products reach the market has fundamentally changed, we explore new avenues to bring healthcare products to market in regions where there are unique needs. In particular, developing commercialization solutions to meet the needs of the healthcare market in the Asia-Pacific region can be more cost effective and may benefit a larger population.

The Ceremax Investment Group was established by members of the USC EMBA Class XXV to pool its financial and intellectual resources to identify investment opportunities. Ceremax will capitalize on the collective experiences and pool of contacts of its members to source, underwrite, and manage these investment opportunities. Additionally, Ceremax will provide a channel for its members to strengthen the relationships first developed in the classroom while attending USC.

• Provided oversight for global product development in multiple international business divisions• Authored and/or attained 12 patents & 3 trademarks on proprietary cancer tests, cancer (gene) therapies, cosmeceuticals, and animal models• Achieved numerous regulatory approvals for cancer tests, cancer therapies, pharmaceuticals, and cosmeceutical products with US FDA, Health Canada, Korean FDA, China SFDA, Taiwanese Ministry of Health, Indian Ministry of Health• Initiated and/or nurtured 5 international, collaborative, cancer research trial programs with universities and hospitals studying colon, lung, and pancreatic cancer; as well as general cancer screening programs that yielded 7 publications supporting cancer products• Championed Elleuxe®/Goodnak® cosmeceutical line  Provided oversight for formulations, safety & effectiveness testing, regulatory strategy  Led branding committee and created marketing materials with external agencies  Created commercialization strategy, sourced US raw materials, hired contract manufacturers• Led and participated in internal and US FDA, CDPH, CE Mark/ISO 13485, and CMDR audits• Advised CEO and CFO on Production Capacity and Supervised Quality System for ISO 13485 and cGMP compliant medical device manufacturing facility

Los Angeles, Ca, Us

Beta Gamma Sigma International Honor Society

• Championed DR-70® colorectal cancer test that accounts for 100% of domestic sales  Patented invention, performed clinical trials, obtained US FDA, KFDA, and CMDR approvals  Created commercialization strategy, advised on first exclusive distribution relationships, led branding committee, created marketing materials with the marketing department • Designed commercialization strategy for in-licensed cervical cancer test, MyHPV Kit®  Developed technical product file in Korea with original manufacturer, created US prototype  Sourced US raw materials, hired contract manufacturers, prepared regulatory filings • Represented company and promoted cancer tests at international cancer meetings • Advised CEO on additional licensed technologies through due diligence research

• Led medical device product development for colon, lung, pancreatic and general cancer tests with an annual budget of approximately $2.4 million USD• Represented company regulatory filings directly with US FDA agency• Managed intellectual property portfolio• Achieved 28% decrease in production error rate through continuous process improvement program in manufacturing

Honolulu, Hawaii, Us

Responsibilities: in charge of research division devoted to the study of selenoprotein biosynthesis and role of selenoproteins in protection from oxidative damage.Projects: identifying supramolecular complexes responsible for selenocysteine incorporation; demonstrating nucleo-cytoplasmic shuttling of selenium incorporation cofactors, defining the role of oxidative stress in neuronal neuropathies caused by elevated glucose levels, defining molecular responses to oxidative stress and links to oncological processes as well as protection from oxidative stress by selenoproteins.

Honolulu, Hi, Us

Principal Investigator: Helen Turner, Ph.DProjects: the effects of cannabinoids on immune cells; oncogenic signaling by cigarette smoke condensates (CSC) in human mast cells; defining the calcium store operated transcriptome in mast cells

Los Angeles, Ca, Us

Performed independent research; served as a teaching assistant in biochemistry (won teaching awards); molecular biology, and immunology. Gave guest lectures: 1) in the freshman biology class on plant physiology and 2) histology class on reproductive tissues and morphological/functional distinctions among gastrointestinal tissues.

Los Angeles, Ca, Us

Principal Investigator: John S. Stephens, Ph. DOccidental College, Los Angeles, CA 90041The overall goal of the research project was to determine if thermal warming from the hydroelectric plant in King Harbor was having an effect on the local fauna, especially as it might have an impact on reef fish. Led monthly ichthyoplankton sample collections; supervised a team of biologists identifying fauna in the plankton trawls; and prepared monthly reports. In addition, created a dichotomous taxonomic tree for identifying the common (top 95% found in our collections) types of marine fish larvae.

Los Angeles, Ca, Us

Supervisor: Gary Jordan, M.A.Occidental College, Los Angeles, CA 90041Monitoring effects of sport fishing on fish stocks at the Salton Sea, California.

Mba, Executive Mba, Class Xxv

Ph.D., Biochemistry, Molecular Biology, Immunology

Ab, Biology, Philosophy